BrainXell focuses on neural cells for therapeutic development. Founded in 2015 by Prof. Su-Chun Zhang with help from the Discovery to Product (D2P) program of University of Wisconsin Madison, it is based on the proprietary technology of directed differentiation of human stem cells (including induced pluripotent stem cells) to highly enriched subclasses of neurons. BrainXell is developing drug discovery / toxicology testing platforms using patient-derived or genetically modified stem cells and provides large-scale production of highly enriched, functionally specialized neural cells to the pharmaceutical and biotechnology industry. BrainXell also aims to develop stem cell therapy for neurological injuries and diseases through collaboration with pharmaceutical and healthcare industry. BrainXell’s mission is to make our brain healthy and well.